MED12
protein-codingmediator complex subunit 12, the group of Mediator complex
Gene summary
The initiation of transcription is controlled in part by a large protein assembly known as the preinitiation complex. A component of this preinitiation complex is a 1.2 MDa protein aggregate called Mediator. This Mediator component binds with a CDK8 subcomplex which contains the protein encoded by this gene, mediator complex subunit 12 (MED12), along with MED13, CDK8 kinase, and cyclin C. The CDK8 subcomplex modulates Mediator-polymerase II interactions and thereby regulates transcription initiation and reinitation rates. The MED12 protein is essential for activating CDK8 kinase. Defects in this gene cause X-linked Opitz-Kaveggia syndrome, also known as FG syndrome, and Lujan-Fryns syndrome. [provided by RefSeq, Aug 2009]
- TNRC11
- FGS1
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~25.6 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: XL
Disease ID:MONDO:0010477
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: XL
Disease ID:MONDO:0010590
Submitter: Orphanet
Inheritance Pattern: XL
Disease ID:MONDO:0010655
Submitter: Orphanet
Inheritance Pattern: XL
Disease ID:MONDO:0012997
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: XL
Disease ID:MONDO:0700092
Submitter: G2P
Inheritance Pattern: XL
Disease ID:MONDO:0010477
Submitter: Orphanet
Inheritance Pattern: XL
Disease ID:MONDO:0100000
Submitter: ClinGen
MED12 is a component of the multisubunit Mediator complex, which is involved in transcriptional regulation of RNA polymerase II-dependent genes. *MED12* was first reported in relation to X-linked *MED12*-related intellectual disability syndrome in 2007 (Risheg et al., PMID: 17334363; Schwartz et al., PMID: 17369503). Missense variants in *MED12* have been reported in individuals with several disease entities within the spectrum of X-linked recessive syndromic intellectual disability. Per criteria outlined by the ClinGen Lumping and Splitting guidelines, we found no difference in molecular mechanism or inheritance pattern underlying the disease entities: 1) Opitz-Kaveggia syndrome, also known as FG syndrome (MIM:305450), 2) Lujan-Fryns syndrome (MIM:309520), and 3) X-linked Ohdo syndrome (MIM:300895). Therefore, these entities were lumped into one disease entity, X-linked *MED12*-related intellectual disability syndrome. The most penetrant phenotype shared by these syndromes is intellectual disability, with other features such as dysgenesis or agenesis of the corpus callosum, blepharophimosis, marfanoid habitus, and anal anomalies having variable expressivity. In all three of these syndromes, carrier females are typically unaffected, but there are a few reports of females with mild intellectual disability and/or facial dysmorphism. More recently, males with intellectual disability without a distinct syndrome, and female patients with *de novo* missense variants or protein truncating variants in *MED12* have also been reported (e.g., PMIDs: 24039113, 30006928, 31536828, 33244165). Eighteen variants in 30 male probands (17 missense and 1 frameshift) and 3 variants in 3 female probands (1 *de novo* nonsense and 2 missense) are included in this curation. Several missense variants are recurrent, including p.Arg961Trp in 10 unrelated individuals in this curation. Variants in this gene segregated with disease in additional family members. More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. This gene-disease relationship is also supported by biochemical function and protein interactions as part of the kinase module of the Mediator complex, functional studies, and an animal model. In summary, there is definitive evidence supporting the relationship between *MED12* and X-linked *MED12*-related intellectual disability syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This gene-disease pair was originally evaluated by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on April 18, 2018. It was reevaluated on October 15, 2025 (SOP Version 11). Although further experimental evidence was added, the classification did not change.
Inheritance Pattern: XL
Disease ID:MONDO:0010655
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: XL
Disease ID:MONDO:0010655
Submitter: G2P
Inheritance Pattern: XL
Disease ID:MONDO:0010590
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: XL
Disease ID:MONDO:0010590
Submitter: G2P
Inheritance Pattern: XL
Disease ID:MONDO:0100000
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Audiologic/Otolaryngologic; Cardiovascular; Craniofacial; Gastrointestinal; Musculoskeletal; Neurologic
Intervention: Cardiovascular
Rationale: Among other findings in Hardikar syndrome, congenital cardiovascular anomalies may occur, and early identificaiton and management may be beneficial
Comments: Aortic root dilatation and ventricular septal defect were reported in one individual and his maternal uncle
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to MED12 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_005120.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 45 | 641 | 19 | 705 | ||
| missense | 5 | 52 | 912 | 161 | 13 | 1143 |
| nonsense | 12 | 10 | 24 | 46 | ||
| start loss | 0 | |||||
| frameshift | 8 | 10 | 6 | 24 | ||
| splice donor/acceptor (+/-2bp) | 2 | 12 | 57 | 1 | 72 | |
| Total | 27 | 84 | 1044 | 803 | 32 | 1990 |
Highest pathogenic variant AF is 0.000005477511
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_005111.2 | 45 | MANE Select | |
| Ensembl | ENSP00000363193.3 | 45 | MANE Select | |
| Ensembl | ENSP00000333125.8 | 45 | Standard | |
| Ensembl | ENSP00000333125.8 | 45 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| med12 | Danio rerio | Structure: neutrophil Quality: decreased amount abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Thyroid hormone signaling pathway - Homo sapiens (human)
- WNT-Ncore
- Developmental Biology
- Gene expression (Transcription)
- Generic Transcription Pathway
Biological Process
- neural tube closure
- regulation of transcription by RNA polymerase II
- transcription initiation from RNA polymerase II promoter
- endoderm development
- heart development
Molecular Function
- RNA polymerase II distal enhancer sequence-specific DNA binding
- chromatin binding
- transcription coregulator activity
- transcription coactivator activity
- protein binding
Cellular Component
- ubiquitin ligase complex
- nucleus
- nucleoplasm
- membrane
- mediator complex
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000374080
- Coding exons
- 45
- Length
- 23898
- Individuals with no LoFs
- 121517
- Homozygous LoFs
- 1
- Heterozygous LoFs
- 0
- Defined
- 121518
- p
- 0.00000411
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 6.58 | 343 | 898 | 0.382 | 0.0000742 | 14199 |
| Missense (PolyPhen) | 66 | 275 | 0.24 | 4257 | ||
| Synonymous | 1.25 | 314 | 343 | 0.914 | 0.0000269 | 4324 |
| Loss of Function | 8.53 | 2 | 88.7 | 0.0226 | 0.00000676 | 1318 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000013 | 0.0000092 | rare |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. This subunit may specifically regulate transcription of targets of the Wnt signaling pathway and SHH signaling pathway. {ECO:0000269|PubMed:16565090, ECO:0000269|PubMed:16595664, ECO:0000269|PubMed:17000779}.;
- Disease
- DISEASE: Lujan-Fryns syndrome (LUJFRYS) [MIM:309520]: Clinically, Lujan-Fryns syndrome can be distinguished from Opitz-Kaveggia syndrome by tall stature, hypernasal voice, hyperextensible digits and high nasal root. {ECO:0000269|PubMed:17369503}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Ohdo syndrome, X-linked (OHDOX) [MIM:300895]: A syndrome characterized by mental retardation, feeding problems, and distinctive facial appearance with coarse facial features, severe blepharophimosis, ptosis, a bulbous nose, micrognathia and a small mouth. Dental hypoplasia and deafness can be considered as common manifestations of the syndrome. Male patients show cryptorchidism and scrotal hypoplasia. {ECO:0000269|PubMed:23395478}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.306
Intolerance Scores
- RVIS EVS
- -1
- RVIS percentile EVS
- 8.47
Essentials
- Essential (CRISPR)
- E
- Essential (CRISPR2)
- E
- Essential (gene trap)
- E
- Indispensability pred.
- E
- Indispensability score
- 0.952
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |